This comprehensive case study explores Kymanox’s approach to combination product remediation and global development through advanced analytical methods, process optimization, and international clinical expansion. Our team of Subject Matter Experts (SMEs) collaborated closely with pharmaceutical stakeholders to implement measurable improvements across regulatory compliance, analytical testing, Design History File (DHF) remediation, process control, and multi-regional clinical studies for synthetic peptide nasal spray orphan drug development.
CHALLENGE
SOLUTION
RESULTS
- Pharmaceutical client required comprehensive project revival upgrading previously rejected synthetic peptide nasal solution FDA application to meet stringent combination product requirements.
- Significant regulatory and technical challenges needed resolution aligning product development with global standards across US, European, Canadian, and Japanese markets.
- International clinical study expansion essential supporting multi-regional product approval and commercialization for orphan indication serving unmet medical needs.
- Enhanced quality systems and lifecycle management solutions required ensuring long-term product compliance, patient safety, and commercial viability.
- Upgraded previously rejected FDA application expanding clinical trials globally across Canada, Europe, and Japan ensuring compliance with combination product regulations.
- Standardized testing methodologies, developed enhanced analytical techniques, and improved process controls eliminating product variability and increasing manufacturing yields.
- Conducted comprehensive gap assessments, remediated Design History Files (DHFs), and implemented new document subtypes and electronic binder systems.
- Housed complete DHF documentation in electronic Quality Management System (eQMS) ensuring regulatory compliance and efficient document control.
- Identified and controlled critical processing parameters linking them to critical quality attributes for improved manufacturing consistency.
- Developed custom lifecycle management solutions improving patient compliance and supporting long-term commercial success.
- Established new particulate matter standards specifically for nasal product applications advancing industry testing practices.
- Successfully eliminated product variability through enhanced analytical methods and process controls ensuring consistent therapeutic delivery.
- Established clear linkages between critical processing parameters and critical quality attributes enabling robust process control and regulatory confidence.
- Achieved increased manufacturing process yields and established groundbreaking particulate matter standards for nasal spray products.
- Secured commercial manufacturing partners ensuring seamless product assembly, packaging, and distribution capabilities supporting global commercialization.
- Successfully initiated international clinical studies across multiple regions advancing product toward multi-regional approval and market access for orphan indication.